Effect of Atorvastatin on E.C.G Changes in Coronary Artery Disease

##plugins.themes.academic_pro.article.sidebar##

Published Jan 1, 2013
https://doi.org/10.18311/ijmds/2013/19819
Download
PDF
Statistic

Downloads

Download data is not yet available.
Volume 2, Issue 1, January 2013

##plugins.themes.academic_pro.article.main##

Harmanjit Singh
Pharmacology, PGIMER, Chandigarh
Anita Gupta
Pharmacology, GMC, Patiala
Vijay Bajaj
Pharmacology, GMC, Patiala
Bakhshish Singh Gill
Medicine, GMC, Patiala,
Jasbir Singh
Pharmacology, GMC, Patiala

Abstract

E.C.G is the most widely used test for both the diagnosing and estimating the prognosis of CAD. ST segment and T wave changes are most commonly evaluated parameters of E.C.G. Atorvastatin have found to decrease ischemic events apart from its hypolipidemic effect. The main objective of this open prospective randomized, controlled study was to evaluate the effect of addition of atorvastatin to conventional antianginal treatment on ST segment and T wave changes on E.C.G. The study was conducted for duration of 2 months in 30 patients of CAD (15 in each group). Group A was started on conventional antianginal treatment and group B was started on Atorvastatin 20 mg once a day at night in addition to conventional treatment. The ECG changes were recorded after 15, 30, 45 and 60 days using 12 lead E.C.G. At the end of the study, no significant difference was found in E.C.G changes between the group A and group B. A slight improvement in ST segment changes in group B patients was observed but the effect was statistically not significant. So, addition of atorvastatin to conventional antianginal treatment did not have a significant effect on reversal of ischemic changes on ECG in patients of CAD.

##plugins.themes.academic_pro.article.details##

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

How to Cite
Singh, H., Gupta, A., Bajaj, V., Gill, B. S., & Singh, J. (2013). Effect of Atorvastatin on E.C.G Changes in Coronary Artery Disease. International Journal of Medical and Dental Sciences, 34–38. https://doi.org/10.18311/ijmds/2013/19819
Crossref
Scopus
Google Scholar
Europe PMC

References

  1. Verri V, Cunha AB, Tessarolo LE et al. Reduction of myocardial ischaemia with Simvastatin in addition to conventional treatment in patients with chronic coronary artery disease. Rev port cardiol 2004; 23:1089-105.
  2. Goldberger AL. Electrocardiography. In Faucy AS, Kasper DL, Longo DL et al, editors. Harrison’s principles of internal medicine. 18th edn. New York: McGrawHill Companies; 2012.p.1831-1839.
  3. Morris F, Brady WJ. ABC of clinical electrocardiography Acute myocardial infarction—Part I. BMJ 2002; 324:831834.
  4. HMG CoA reductase inhibitors. In Finkel R, Clark MA, Cubeddu LX et al, editors. Lippincott's Illustrated Reviews: Pharmacology. 4TH ed. New York and New Delhi: Lippincott William and Wilkins and Wolters Kluwer; 2009.p.253-255.
  5. Schoming A, Mehilli J, Holle H et al. Statin treatment following coronary artery stenting and one-year survival. J Am Coll Cardiol 2002; 40:854-861.
  6. Blumenthal RS, Cohn G, Schulman SP. Medical therapy versus coronary angioplasty in stable coronary artery disease: a critical review of the literature. J Am Coll Cardiol 2000; 36:668-673.
  7. Gaddam V, Li DY, Mehta JL. Antithrombotic effects of atorvastatin – An effect unrelated to lipid lowering. J of Cardiovascular Pharmacology of Therapeutics 2002; 7(4):247-253.
  8. Amarenco P, Bogousslavsky J, Callahan A et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006; 355:549-59.
  9. Vondrakova D, Ostadal S, Kruger A. Immediate effect of intensive atorvastatin therapy on lipid parameters in patients with acute coronary syndrome. Lipids In Health And Disease 2010; 9:71.